CVS Stock Recent News
CVS LATEST HEADLINES
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
CVS Health gained 50% over the three-month period while Deckers fell nearly as much.
We're nearing the end of the calendar-year Q1, with many S&P 500 stocks delivering strong performances year-to-date despite recent volatility stemming from tariff talks and other economic developments.
On the final day of the first quarter of 2025, Madison Mills and Julie Hyman take a look at the best and worst-performing stocks and sectors of the year so far. Among the worst performers are Deckers (DECK) and Tesla (TSLA), while CVS Health (CVS) led gains.
CVS Health experienced a significant turnaround in 2025, with shares up nearly 50% after a 44% decline in 2024. The recent rally is not driven by great results or strong guidance under new CEO leadership, but rather bad ones that just weren't as terrible as expected. CVS's 2025 outlook includes modest revenue growth, improved operating income, and a focus on stabilizing margins and profitability.
The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far.
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Tariff turmoil has continued to provide intense volatility for the stock market, with certain sector seeing outsized losses as investors price in the risk of tariffs being put in place on a number of sectors and countries which export products to the U.S.
CVS Health (CVS) closed at $67.20 in the latest trading session, marking a +1.08% move from the prior day.
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.